

Table 3 Prioritization of outcomes and outcome measures in health technology assessments (HTAs) of Alzheimer’s disease (AD) drugs

<b>Outcome</b>	<b>ENGLAND</b>	<b>GERMANY</b>	<b>THE NETHERLANDS</b>
<i>Cost-effectiveness</i>	<b>Prioritized</b> Economic modelling conducted	<b>Not prioritized</b> No economic modelling conducted	<b>Not prioritized</b> No economic modelling conducted
<i>Quality of life</i>	<b>Prioritized</b> Derived from outcomes measured with clinical scales to inform the economic modelling	<b>Not prioritized</b> Method requirements (e.g. 70% follow up rate) prevented influence of outcome on decisions	<b>Not prioritized</b> No assessment
<i>Outcomes measured with clinical scales</i>	<b>Prioritized</b> Cognition (including Mini-Mental State Examination; MMSE), Activities of daily living (ADL) and multi-domain change prioritized	<b>Prioritized</b> Global assessment outcomes less prioritized	<b>Prioritized</b> Mini-Mental State Examination (MMSE) less prioritized / not accepted
<i>Adverse effects</i>	<b>Not prioritized</b> Formally included but not referred to in decision	<b>Prioritized</b> Included and referred to in decision	<b>Prioritized</b> Included and referred to in decision
<i>Outcomes relevant to people with Alzheimer’s Disease</i>	<b>Not prioritized</b> Focus on evidence from randomised controlled trials that measure outcomes with clinical scales	<b>Not prioritized</b> Focus on evidence from randomised controlled trials that measure outcomes with clinical scale	<b>Not prioritized</b> Focus on evidence from randomised controlled trials that measure outcomes with clinical scale
<i>Carers’ outcomes</i>	<b>Prioritized</b> Included as primary endpoint but lower priority than outcomes for person with AD; methodological challenges prevent influence of outcome on decisions	<b>Not prioritized</b> Not considered responsibility of health care system; relevant only if impact on patient outcomes	<b>Not prioritized</b> Potential role in economic modelling but not carried out so far for AD drugs
<i>Institutionalization</i>	<b>Prioritized</b> Included in economic modelling (by linking outcomes with clinical scales to non-AD data sets)	<b>Not prioritized</b> Absence of trial evidence; method requirements also prevent influence of outcome on decisions	<b>Not prioritized</b> Not included due to absence of trial evidence